Quality of life is a mutual responsibility for all of us. At Bayer, we’ve been providing innovative therapeutic solutions that help improve lives for over 150 years. Everything we do revolves around human and animal health and is reflected in our mission “Science For A Better Life”
Our scientists work tirelessly in pursuit of new therapies, especially in areas where there is high unmet medical need. Cardiovascular disease and cancer – two of the most common causes of death worldwide – are both areas where our scientists are working to develop targeted therapies that will ensure patients can be treated more effectively in future. In addition to cardiovascular disease and cancer, we also focus on therapeutic solutions for hematology, ophthalmology and women’s health. For example, therapeutic options for Hemophilia A, a genetic disease that affects some 400,000 people around the world, as well as a broad range of products for women who want safe and convenient birth control, as well as products that alleviate menopause symptoms. Other recent developments include new treatments for pulmonary hypertension.
Our mission is to research, develop, manufacture and market innovative products that improve the health of people throughout the world.
Medical progress for the benefit of patients
Although Aspirin was originally developed in 1899, our scientists continue to discover new aspects of this pharmaceutical. Today, we continue this tradition with the development of products that help people who want to choose their own medicines to treat or prevent everyday ailments as well as dietary supplements to support a healthy diet.
200 leading historians have concluded that neither Einstein’s theory of relativity nor the nuclear bomb, nor even the power of computers and the internet have had a stronger impact on society in the 20th century than the Pill1. We are a world leader in the field of women's health, especially in hormonal contraceptive products.
Some 2.5 million people worldwide suffer from multiple sclerosis (MS), Bayer was one of the first companies to offer a treatment for this autoimmune disease.
In thrombosis management, Bayer has developed the first direct oral Factor Xa inhibitor used for the prevention and treatment of life-threatening blood clots.
We are proud to be able to help improve outcomes for five of the leading causes of vision loss in the working-age and elderly population. Eighty percent2 of all vision impairment could be prevented or cured. Bayer is committed to helping reduce the number of people impacted globally by visual impairment through innovative products and research.
Bayer is delivering science for a better life by advancing a portfolio of innovative treatments. The oncology franchise at Bayer now includes three oncology products and several other compounds in various stages of clinical development. Together, these products reflect the company’s approach to research, which prioritizes targets and pathways with the potential to impact the way that cancer is treated.
At Bayer, scientists discovered a new way to treat pulmonary hypertension. Its distinct mode of action has the potential to overcome a number of limitations of previously approved treatments for pulmonary arterial hypertension and, and is the first drug which has shown clinical benefits in patients with inoperable chronic thromboembolic pulmonary hypertension, where up until then no approved medication was available.